Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tivumecirnon · FLX-475, FLX-3475

Small molecule · Antagonist of C-C chemokine receptor type 4 (CCR4) · developed by RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Phase 1/2 Most advanced trial (none active)
GSK Developer
2 Registered trials

What is Tivumecirnon?

Tivumecirnon is an orally available small molecule that antagonizes the chemokine receptor CCR4, inhibiting its binding to signaling molecules. By blocking CCR4, it is intended to prevent regulatory T-cells from being recruited to the tumor microenvironment. It is being studied in advanced cancer and advanced melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FLX-475, FLX-3475
Drug type
Small molecule
Targets
C-C chemokine receptor type 4 (CCR4)
Mechanism
Antagonist of C-C chemokine receptor type 4 (CCR4)
Pathways
regulatory T-cell recruitment to the tumor microenvironment
Therapy area
Oncology
Developer
RAPT Therapeutics, Inc., a member of the GSK plc group of companies (GSK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
R1T69T65FJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04894994 Phase 2 Advanced Melanoma Terminated GSK
NCT03674567 Phase 1/2 Advanced Cancer Completed GSK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAdvanced Melanoma

Other drugs acting on CCR4

More from RAPT Therapeutics, Inc., a member of the GSK plc group of companies

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the GSK page.

Follow GSK, the company behind Tivumecirnon

See GSK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GSK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.